<DOC>
	<DOCNO>NCT00526110</DOCNO>
	<brief_summary>Phase I Objectives Primary : 1 . The primary objective study determine maximum tolerate dose ( MTD ) Docetaxel combine 5-Fluorouracil Oxaliplatin ( D-FOX ) patient untreated , locally unresectable metastatic adenocarcinoma stomach gastroesophageal junction ( GEJ ) . Secondary : 1 . To determine qualitative quantitative toxicity reversibility toxicity combination . Phase II Objectives Primary : 1 . To assess time cancer progression D-FOX treatment regimen . Secondary : 1 . To assess response rate D-FOX treatment regimen . 2 . To determine qualitative quantitative toxicity reversibility toxicity combination treatment regimen . 3 . Determine overall survival . 4 . Perform exploratory investigation effect D-FOX phenotypic abnormality blood .</brief_summary>
	<brief_title>Docetaxel , 5-Fluorouracil Oxaliplatin Adenocarcinoma Stomach Gastroesophageal Junction Patients</brief_title>
	<detailed_description>Oxaliplatin 5-FU chemotherapy drug commonly use treat certain kind cancer . Oxaliplatin interfere DNA . 5-FU interferes cell metabolism . Docetaxel interfere cell division . Before start treatment study , call `` screening test '' . These test help doctor decide eligible take part study . You ask question medical history complete physical exam . You around 1 tablespoon blood drawn routine test . You height weight measure . You chest x-ray electrocardiogram ( ECG - test measure electrical activity heart ) . You also chest x-ray compute tomography ( CT ) scan check size location tumor . Women able child must negative blood pregnancy test . If find eligible take part study , receive treatment 5-FU infusion vein use continuous 24- hour portable pump . This start Day 1 continue 48 hour . You need carry pump time 48 hour . The pump size Sony WalkmanÂ® . You also receive oxaliplatin infusion vein 2 hour Day 1 . Docetaxel give infusion 60 minute Day 1 . You 12 day rest chemotherapy treatment . These drug may give outpatient . Treatment repeat Day 15 . Two 14-day treatment period call one cycle . You ask fill side effect sheet throughout participation research study . You ask question regard nausea , hair loss , fatigue , meal , question regard daily activity . Before dose chemotherapy ( every 14 day ) , 1 teaspoon blood drawn routine test . If cancer get bad experience intolerable side effect , take study doctor discus treatment option . You ask come follow-up visit M.D . Anderson 2-3 month treatment end possible . At visit , full physical , one tablespoon blood drawn routine test , chest x-ray , CT magnetic resonance imaging ( MRI ) scan . This investigational study . Oxaliplatin approve treatment colon rectal cancer approve US use treatment gastric cancer . Docetaxel 5-FU commonly use drug gastric cancer commercially available . The combination 3 drug ( docetaxel + oxaliplatin + 5-FU ) investigational . A total 106 patient take part study . All enrol M.D . Anderson .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Gastrointestinal Diseases</mesh_term>
	<mesh_term>Digestive System Diseases</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>1 . Histologically documented adenocarcinoma stomach Gastroesophageal Junction ( GEJ ) . 2 . Age &gt; 18 year ; 3 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 01 ; 4 . Chemotherapy : No prior chemotherapy permit metastatic disease . Use prior chemotherapy adjuvant and/or neoadjuvant set part radiosensitization permit , provide minimum time completion treatment study entry least 12 month ; 5 . Radiation : Patients may prior radiation therapy exceed 25 % bone marrow reserve provide recovered acute , toxic effect radiotherapy prior registration . A minimum 14 day must elapse since end radiotherapy . 6 . Previous Surgery : Previous surgery permit provide wound healing occur prior registration . Minimum 14 day must elapse major surgery start chemotherapy . 7 . At least one target lesion &gt; 20 mm ( &gt; 10 mm spiral CTscan ) . If indicator lesion previously irradiate field , clear disease progression irradiate lesion new lesion previously irradiate field accept 8 . Adequate baseline bone marrow , hepatic renal function , define follow : Neutrophils &gt; 1.5 * 10*9/L platelet &gt; 100 * 10*9/L ; Bilirubin &lt; 1.5 * upper limit normal range ( ULN ) ; aspartate aminotransferase ( AST SGOT ) and/or alanine aminotransferase ( ALT SGPT ) &lt; 2.5 * ULN ; Serum creatinine &lt; 1.5 * ULN ; 9 . Patients must give write informed consent participate study . 10 . Patients male female reproductive potential ( ie , menopausal less 1 year surgically sterilize ) must practice effective contraceptive measure throughout study . Women childbearing potential must negative pregnancy test ( serum urine ) within 14 day prior registration . 1 . Concurrent anticancer therapy 2 . Pregnant lactate woman 3 . History prior malignancy except adequately treat basal cell squamous cell skin cancer ; situ cervical cancer malignancy patient diseasefree 5 year ; 4 . Brain metastases 5 . Patients active uncontrolled infection serious illness medical condition , include patient history chronic alcohol abuse , hepatitis , HIV and/or cirrhosis 6 . History psychiatric condition might impair patient 's ability understand comply requirement study provide inform consent . 7 . Known hypersensitivity drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Gastrointestinal Diseases</keyword>
	<keyword>Adenocarcinoma Stomach</keyword>
	<keyword>Gastroesophageal Junction Cancer</keyword>
	<keyword>Cancer Stomach</keyword>
	<keyword>5-Fluorouracil</keyword>
	<keyword>5-FU</keyword>
	<keyword>Adrucil</keyword>
	<keyword>Efudex</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Oxaliplatin</keyword>
	<keyword>Eloxatin</keyword>
	<keyword>Taxotere</keyword>
	<keyword>Esophagus</keyword>
</DOC>